Evaluation of etoricoxib in patients undergoing total knee replacement surgery in a double-blind, randomized controlled trial

BMC Musculoskeletal Disorders

Dimitris A Papanicolaou⁵  Sean P Curtis⁵  Denesh K Chitkara⁵  Anish Mehta¹  Sandhya Shah⁵  Liang Chen⁴  Harold S Minkowitz³  Paul M Peloso⁵  Eugene Viscusi⁶  Narinder Rawal² 

[1] Office of the Chief Medical Officer, Merck & Co., Inc, Whitehouse Station, NJ, USA;Department of Anaesthesiology and Intensive Care, Orebro University Hospital, Örebro, SE 701 85, Sweden;Memorial Hermann Memorial City Medical Center, Houston, TX, USA;Late Development Statistics, Merck & Co., Inc, Whitehouse Station, NJ, USA;Clinical Research, Merck & Co., Inc, Whitehouse Station, NJ, USA;Department of Anesthesiology, Thomas Jefferson University, Philadelphia, PA, USA

关键词: Pain upon movement;    Pain at rest;    Total knee replacement;    Morphine consumption;    Ibuprofen;    Etoricoxib;   

Others  :  1129388
DOI  :  10.1186/1471-2474-14-300

 received in 2012-09-28, accepted in 2013-09-18,  发布年份 2013

【 摘 要 】

Background

Optimal postoperative pain management is important to ensure patient comfort and early mobilization.

Methods

In this double-blind, placebo- and active-controlled, randomized clinical trial, we evaluated postoperative pain following knee replacement in patients receiving placebo, etoricoxib (90 or 120 mg), or ibuprofen 1800 mg daily for 7 days. Patients ≥18 years of age who had pain at rest ≥5 (0–10 Numerical Rating Scale [NRS]) after unilateral total knee replacement were randomly assigned to placebo (N = 98), etoricoxib 90 mg (N = 224), etoricoxib 120 mg (N = 230), or ibuprofen 1800 mg (N = 224) postoperatively. Co-primary endpoints included Average Pain Intensity Difference at Rest over Days 1–3 (0- to 10-point NRS) and Average Total Daily Dose of Morphine over Days 1–3. Pain upon movement was evaluated using Average Pain Intensity Difference upon Knee Flexion (0- to 10-point NRS). The primary objective was to demonstrate analgesic superiority for the etoricoxib doses vs. placebo; the secondary objective was to demonstrate that the analgesic effect of the etoricoxib doses was non-inferior to ibuprofen. Adverse experiences (AEs) including opioid-related AEs were evaluated.

Results

The least squares (LS) mean (95% CI) differences from placebo for Pain Intensity Difference at Rest over Days 1–3 were -0.54 (-0.95, -0.14); -0.49 (-0.89, -0.08); and -0.45 (-0.85, -0.04) for etoricoxib 90 mg, etoricoxib 120 mg, and ibuprofen, respectively (p < 0.05 for etoricoxib vs. placebo). Differences in LS Geometric Mean Ratio morphine use over Days 1–3 from placebo were 0.66 (0.54, 0.82); 0.69 (0.56, 0.85); and 0.66 (0.53, 0.81) for etoricoxib 90 mg, etoricoxib 120 mg, and ibuprofen, respectively (p < 0.001 for etoricoxib vs. placebo). Differences in LS Mean Pain Intensity upon Knee Flexion were -0.37 (-0.85, 0.11); -0.46 (-0.94, 0.01); and -0.42 (-0.90, 0.06) for etoricoxib 90 mg, etoricoxib 120 mg, and ibuprofen, respectively. Opioid-related AEs occurred in 41.8%, 34.7%, 36.5%, and 36.3% of patients on placebo, etoricoxib 90 mg, etoricoxib 120 mg, and ibuprofen, respectively.

Conclusions

Postoperative use of etoricoxib 90 and 120 mg in patients undergoing total knee replacement is both superior to placebo and non-inferior to ibuprofen in reducing pain at rest and also reduces opioid (morphine) consumption.

Clinical trial registration

NCT00820027

【 授权许可】

   
2013 Rawal et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Marx RG, Jones EC, Atwan NC, Closkey RF, Salvati EA, Sculco TP: Measuring improvement following total hip and knee arthroplasty using patient-based measures of outcome. J Bone Joint Surg Am 2005, 87:1999-2010.
• [2]Jones CA, Beaupre LA, Johnston DW, Suarez-Almazor ME: Total joint arthroplasties: current concepts of patient outcomes after surgery. Clin Geriatr Med 2005, 21:527-532.
• [3]Ethgen O, Bruyere O, Richy F, Dardennes C, Reginster JY: Health-related quality of life in total hip and knee arthroplasty. J Bone Joint Surg Am 2004, 86:963-969.
• [4]Kurtz S, Mowat F, Ong K, Chan N, Lau E, Halpern M: Prevalence of primary and revision total hip and knee arthroplasty in the United States from 1990 through 2002. J Bone Joint Surg Am 2005, 87:1487-1497.
• [5]Kurtz S, Ong K, Lau E, Mowat F, Halpern M: Projections of primary and revision hip and knee arthroplasty in the United States from 2005 to 2030. J Bone Joint Surg Am 2007, 89:780-785.
• [6]Kehlet H: Surgical stress: the role of pain and analgesia. Br J Anaesth 1989, 63:189-195.
• [7]Apfelbaum JL, Ashburn MA, Connis RT, Gan TJ, Nickinovich DG, Caplan RA, Carr DB, Ginsberg B, Green CR, Lema MJ, Rice LJ: Practice guidelines for acute pain management in the perioperative setting. An updated report by the American Society of Anesthesiologists Task Force on acute pain management. Anesthesiology 2012, 116:248-273.
• [8]Cawley D, Bennett MI: Management of pain. Br J Hosp Med 2009, 70:197-201.
• [9]Peters C, Shirley B, Erickson J: The effect of a new multimodal perioperative anesthetic regimen on postoperative pain, side effects, rehabilitation, and length of hospital stay after total joint arthroplasty. J Arthroplasty 2006, 21(6 Suppl 2):132-138.
• [10]Kehlet H, Dahl JB: The value of “multimodal” or “balanced analgesia” in postoperative pain treatment. Anesth Analg 1993, 77:1048-1056.
• [11]Rasmussen GL, Malmstrom K, Bourne MH, Jove M, Rhondeau SM, Kotey P, Ang J, Aversano M, Reicin AS: Etoricoxib Postorthopedic Study Group: Etoricoxib provides analgesic efficacy to patients after knee or hip replacement surgery: a randomized double-blind, placebo-controlled study. Anesth Analg 2005, 101:1104-1111.
• [12]Riendeau D, Percival MD, Brideau C, Charleson S, Dube D, Ethier D, Falgueyret JP, Friesen RW, Gordon R, Greig G, Guay J, Mancini J, Ouellet M, Wong E, Xu L, Boyse S, Visco D, Girard Y, Prasit P, Zamboni R, Rodger W, Gresser M, Ford-Hutchinson AW, Young RN, Chan CC: Etoricoxib (MK-0663): Preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J Pharmacol Exp Ther 2001, 96:558-566.
• [13]Dworkin RH, Turk DC, Peirce-Sandner S, Burke LB, Farrar JT, Gilron I, Jensen MP, Katz NP, Raja SN, Rappaport BA, Rowbotham MC, Backonja MM, Baron R, Bellamy N, Bhagwagar Z, Costello A, Cowan P, Fang WC, Hertz S, Jay GW, Junor R, Kerns RD, Kerwin R, Kopecky EA, Lissin D, Malamut R, Markman JD, McDermott MP, Munera C, Porter L, et al.: Considerations for improving assay sensitivity in chronic pain clinical trials: IMMPACT recommendations. Pain 2012, 153:1148-1158.
• [14]Crowe BJ, Xia HA, Berlin JA, Watson DJ, Shi H, Lin SL, Kuebler J, Schriver RC, Santanello NC, Rochester G, Porter JB, Oster M, Mehrotra DV, Li Z, King EC, Harpur ES, Hall DB: Recommendations for safety planning, data collection, evaluation and reporting during drug, biologic and vaccine development: a report of the safety planning, evaluation, and reporting team. Clin Trials 2009, 6:430-440.
• [15]Zeger SL, Liang KY: An overview of methods for the analysis of longitudinal data. Stat Med 1992, 11:1825-1839.
• [16]Miettinen OS, Nurminen M: Comparative analysis of two rates. Stat Med 1985, 4:213-226.
• [17]Wu CL, Rowlingson AJ, Partin AW, Kalish MA, Courpas GE, Walsh PC, Fleisher LA: Correlation of postoperative pain to quality of recovery in the immediate postoperative period. Reg Anesth Pain Med 2005, 30:516-522.
• [18]Lin J, Zhang L, Yang H: Perioperative administration of selective cyclooxygenase-2 inhibitors for postoperative pain management in patients after total knee arthroplasty. J Arthroplasty 2012. http://dx.doi.org/10.1016/j.arth.2012.04.008 webcite [Epub ahead of print]
• [19]Daniels SE, Bandy DP, Christensen SE, Boice J, Losada MC, Liu H, Mehta A, Peloso PM: Evaluation of the dose range of etoricoxib in an acute pain setting using the postoperative dental pain model. Clin J Pain 2011, 27:1-8.
• [20]Viscusi ER, Frenkl TL, Hartrick CT, Rawal N, Kehlet H, Papanicolaou D, Gammaitoni A, Ko AT, Morgan LM, Mehta A, Curtis SP, Peloso PM: Perioperative use of etoricoxib reduces pain and opioid side-effects after total abdominal hysterectomy: a double-blind, randomized, placebo-controlled phase III study. Curr Med Res Opin 2012, 28:1323-1335.
• [21]Gill GS, Mills D, Joshi AB: Mortality following primary total knee arthroplasty. J Bone Joint Surg Am 2003, 85-A:432-435.
• [22]Pellegrini VD Jr, Donaldson CT, Farber DC, Lehman EB, Evarts CM: The Mark Coventry Award: prevention of readmission for venous thromboembolism after total knee arthroplasty. Clin Orthop Relat Res 2006, 452:21-27.
• [23]Jacobs JJ, Mont MA, Bozic KJ, Della Valle CJ, Goodman SB, Lewis CG, Yates AC Jr, Boggio LN, Watters WC 3rd, Turkelson CM, Wies JL, Sluka P, Hitchcock K: American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am 2012, 94:746-747.
• [24]Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C: Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. BMJ 2006, 332:1302-1308.
• [25]Mantilla CB, Horlocker TT, Schroeder DR, Berry DJ, Brown DL: Frequency of myocardial infarction, pulmonary embolism, deep venous thrombosis, and death following primary hip or knee arthroplasty. Anesthesiology 2002, 96:1140–1146. Erratum in. Anesthesiology 2002, 97:531.
• [26]Nüesch E, Trelle S, Reichenbach S, Rutjes AW, Tschannen B, Altman DG, Egger M, Jüni P: Small study effects in meta-analyses of osteoarthritis trials: meta-epidemiological study. BMJ 2010, 341:c3515.